Bavarian Nordic Secures Massive Order for Smallpox Vaccine

Contract Worth $120 Million

Replenishing US Stockpiles for Future Preparedness

Bavarian Nordic, a leading biotechnology company specializing in vaccines, has received a significant order worth $120 million from the United States government for the manufacturing of JYNNEOS Smallpox and Monkeypox Vaccine. This order is aimed at bolstering the US inventory of bulk vaccine, essential for future manufacturing and potential public health emergencies related to smallpox or mpox (monkeypox).

JYNNEOS, approved by the US Food and Drug Administration (FDA), provides protection against both smallpox and mpox. The vaccine is non-replicating, making it suitable for individuals with compromised immune systems. The large order reflects the growing recognition of the need for preparedness against emerging infectious diseases.

Bavarian Nordic's expertise in vaccine development and manufacturing has positioned the company as a key partner in ensuring the availability of essential vaccines for the US population. This latest contract highlights the company's proactive approach in addressing potential health threats and its commitment to safeguarding public health.